WASHINGTON — President Trump’s nominee to head the Department of Health, Robert F. Kennedy Jr., has invested in gene-editing technology and owes substantial advances on several books, according to financial disclosures released ahead of his hearings in confirmation.
The disclosures provide the clearest view yet of RFK Jr’s investments, employment and potential conflicts of interest. They show he plans to divest his shares, including his stakes in biotechnology companies CRISPR Therapeutics AG and Dragonfly Therapeutics. He is also leaving positions at his law firm and the anti-vaccine nonprofit Children’s Health Defense.
Trump tapped RFK Jr. to lead the Department of Health and Human Services after Kennedy ended his presidential campaign and supported Trump. Confirmation hearings have not yet been scheduled.
Already have an account? Log in
See all packages
Tom GerkenTechnology journalistGetty ImagesMany TikTok users rely on the app as a source of income…
Chris Szagola/Cal Sport Media/Newscom/Mega AgencyTHE Kansas City Chiefs are chasing an extraordinary "three-peat" as Super…
LOS ANGELES (AP) — Nearly a hundred jurors packed a Los Angeles courtroom again Wednesday…
Lactose intolerance is a widespread disease that affects millions of people worldwide. For those experiencing…
THESSALONIKI, Greece -- A marble statue of a woman more than 2,000 years old was…
Jewelry designer Lynn Ban, who starred in the Netflix reality series "Bling Empire: New York,"…